🔗 Share this article Social Media Content Creators Driving Unofficial Trade for Unlicensed Weight-Loss Drug A shadow market for unapproved slimming medications is being driven by TikTok fitness influencers and vendors on messaging platforms, based on new investigations. Experimental Drug Acquiring Popularity Via Social Media The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its alleged fat-burning properties. Followers are encouraged to contact these profiles privately for supplier links, while also receiving discount codes. Active Trade on Messaging Platforms Separately, a flourishing trade exists on messaging services, where groups with thousands of participants share comparison images, injection guides and assertions of rapid UK delivery. Sellers market the substance there before directing customers to other platforms for purchases. Learning About Retatrutide Retatrutide is an investigational injection developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could assist individuals lose up to 25% of their body weight. Referred to as the “triple G”, the substance is being promoted digitally as the next Ozempic. Healthcare Professionals Voice Concerns Nevertheless, physicians and pharmacists have warned that the sale of what is still an unlicensed drug in the UK is a cause for concern and could lead to individuals administering substances of uncertain source. Some professionals said the demand for retatrutide could be connected to the rising cost of licensed weight loss products such as Mounjaro. Regulatory Position and Enforcement Marketing the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unapproved drug that cannot be marketed or distributed for personal consumption under the Human Medicines Regulations 2012. Several content creators try to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and supply can still breach medicines, advertising, and customer regulations, potentially leading to fines, legal action or prison. Service Response and Material Removal According to the social media company, the service has taken down problematic content and prohibited associated keywords and query recommendations. The organization stated it was committed to keeping the platform secure and allocating resources in enhancing compliance measures. Digital Marketplace Activities Investigations also found communities with up to nine thousand participants marketing the experimental drug using Telegram's built-in search feature, which operates like a public directory. Typing “retatrutide” immediately brings up channels with thousands of users, filled with photos of slimming results, positive testimonials and step-by-step instructions for mixing or administering at residence. After moments of entering one group, a vendor shared contact information, where most purchases take place. The seller sent an instruction manual and promised delivery within two days. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another shared a image of a alleged testing documentation. Not one asked about body mass, health issues or previous experience. Item Details and Costs Within these communities, messages display black plastic packages with postal service labels, stating to contain new batches. One communication stated: “It took eight of us to load them this morning.” Customers can select between dry substance containers, prepared at residence with sterile water, or ready-to-use pens usually priced at £160 for 20mg. When questioned how long a pen should last, vendors give contradictory responses varying between a several days to “depends on your body”. Service Moderation and Safety Measures A spokesperson for Telegram stated it regularly moderated harmful material on its service including content that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”. Medical Expert Cautions “Individuals are injecting materials they can’t verify. Even if the research behind this drug is valid, these digital products may not contain what they claim,” stated a pharmacy expert, the director of pharmacy at a pharmacy service. A medical professional of Asda Online Doctor connected the surge in interest to recent price rises for authorized slimming drugs such as Mounjaro. “With prices rising, individuals are using online platforms. But counterfeit treatments are highly risky. You cannot know what’s contained or whether the environment they were produced in was clean,” she explained. Her staff has already seen patients harmed by self-injection from unverified suppliers. “We understand the frustration, but buying from messaging apps or WhatsApp is gambling with your well-being,” said Wyllie. “These materials could be contaminated or improperly measured.” Producer Position A representative from Eli Lilly stated the substance was in third stage research studies and had not been evaluated or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for human use,” they said, noting that any product “falsely representing itself as a company experimental product not yet approved … may expose users to possibly significant health risks”.